MMCM
PFE icon

Murphy & Mullick Capital Management’s Pfizer PFE Stock Holding History

Murphy & Mullick Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Buy
19,904
+1,690
+9% +$44.2K 0.28% 80
2026
Q1 		$511K Buy
18,214
+883
+5% +$23.5K 0.38% 63
2025
Q4 		$432K Buy
17,331
+3,849
+29% +$97.1K 0.31% 72
2025
Q3 		$333K Buy
13,482
+1,840
+16% +$45.4K 0.25% 88
2025
Q2 		$279K Buy
11,642
+2,028
+21% +$47.3K 0.23% 98
2025
Q1 		$244K Buy
9,614
+739
+8% +$19.3K 0.24% 103
2024
Q4 		$235K Buy
+8,875
New +$241K 0.22% 97

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Murphy & Mullick Capital Management's PFE Position: Q2 2026 in Review

Murphy & Mullick Capital Management increased its Pfizer (PFE) stake by 9.3% in Q2 2026, buying an estimated $44.2K and bringing the position to 19,904 shares worth $453K. The position accounts for 0.28% of the portfolio, ranked #80.

Murphy & Mullick Capital Management first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $511K in Q1 2026. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Murphy & Mullick Capital Management held 19,904 shares of Pfizer worth $453K as of Q2 2026.
  • Murphy & Mullick Capital Management bought 1,690 Pfizer shares in Q2 2026, an estimated $44.2K.
  • Pfizer made up 0.28% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #80 holding.
  • Murphy & Mullick Capital Management first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Murphy & Mullick Capital Management's Pfizer position peaked at $511K in Q1 2026.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.